Weekly Roundup for JUNE 3, 2022: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
How to Talk to Children About the Texas Shooting
There is no easy way to talk to children about the tragic events in Uvalde Texas. Here are some resources for parents and caregivers.
More Data on Second Generation Antipsychotic Medications and Gestational Diabetes
Second-generation antipsychotic medications associated with high metabolic risk (quetiapine, olanzapine, and clozapine) were associated with increased risk of gestational diabetes; other antipsychotics were not.
Essential Reads: Neurodevelopmental Outcomes in Children with Prenatal Exposure to Benzodiazepines and Z-Drugs
Our data regarding prenatal exposure to BZDs and/or z-drugs and risk of neurodevelopmental outcomes is still sparse.
Prenatal Exposure to Stress, Alterations in Fetal Brain Development Associated with Neurodevelopmental Outcomes
Fetal brain development is altered by elevated maternal distress and has adverse infant social-emotional and cognitive outcomes.
Weekly Roundup for MAY 13, 2022: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
Ecological Momentary Assessment: Innovative Strategies for Improving the Care of Women at Risk of Postpartum Depression
Using a wearable device to track daily symptoms of postpartum depression was viewed as acceptable and clinically useful by participants and clinicians.
APA Launches New Initiative to Address Gaps in the Treatment of Perinatal Mental Health Problems
This initiative will gauge mental health clinicians’ experience with and attitudes around treating pregnant women with mental and substance use disorders in order to identify training gaps.
Announcing Planned Documentary on Postpartum Depression: More Than Blue
Interested in telling your story or know of others who wish to share their PPD journey? We seek those who may be interested in participating in the documentary in some capacity.
Sepranolone: A New Treatment for PMDD?
In this phase II study, sepranolone 10 mg administered subcutaneously during the late luteal phase reduced PMDD symptoms more than placebo.